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Objective: Whitematter hyperintensities (WMHs)were often found inmigraine patients. The
aim of study was to characterize WMHs, assess their prevalence, determine relationship to
clinical symptoms and homocysteine levels in migraine females.
Methods: 69 women 38 with migraine without aura (MO), 31 with migraine with aura (MA)
whounderwent brainMRIwith 1.5T scannerwere enrolled. TheWMHsnumber, location and
size in FLAIR sequence were evaluated. Migraine severity was measured by pain intensity,
number of attacks per month and MIDAS scale.
Results: WMHs were found in 39.1% females. There was no WMHs and migraine type
correlation. The total WMHs number was higher in MO ( p = 0.027). Patients with WMHs
were older ( p = 0.025), have higher BMI ( p = 0.042), suffered longer ( p = 0.001), more often had
positive pregnancy history ( p = 0.010) and less frequent prodromal symptoms. The age of
onset, migraine's severity and homocysteine did not correlate with WMHs. No effect of
antimigraine medication and oral contraceptive pills (OCP) was found. Both in MO and MA
groupsWMHswere located only supratentorially. InMO femalesWMHsweremainly located
in one cerebral hemisphere ( p = 0.024) whereas in MA were found bilaterally. WMHs were
most commonly located in the frontal lobes. In MO lesions were small ≤3 mmand present in
almost all MO patients ( p = 0.027).
Conclusion: WMHs are present in more than one third of migraine females, regardless of
aura. WHMs are located supratentorially, subcortically and in the frontal lobes. Older age,
longer disease's duration, obesity and positive history of pregnancy are main risk factors for
WMHs. Symptomatology and migraine severity, hyperhomocysteinemia, OCP and anti-
migraine medications do not increase WMHs.
© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.* Corresponding author at: Department of Neurology, The Holy Family Specialist Hospital, Rudna Mala 600, 36-060 Glogow Malopolski,
Poland.
E-mail address: iwona.rosciszewska@op.pl (I. Rościszewska-Żukowska).
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0028-3843/© 2018 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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that affects approximately 10–15% of the general population.
Its incidence has been gradually increasing in recent
years; by 15.3% over the past decade [2]. It provokes
signiﬁcant disability and affects negatively the quality of
life [3]. In Polish population the incidence is about 10%, three
times more often in women than in men [4]. Among patients
with migraine various vascular pathologies are found in the
brain magnetic resonance imaging: mainly white matter
hyperintensities (WMHs) and subclinical infarcts mostly
located in posterior circulation territory [5]. Results of
previous studies concerning WMHs, relationship with type
of migraine, sex and age are not conclusive. It has been
reported, that WMHs are two times more frequent in
migraine patients than in general population [6,7]. Accord-
ing to Bashir et al. it is even four times more frequent [8],
while other authors report that its prevalence is not
different from the healthy population [9]. They are found
in 9–59% of migraine patients, according to some research-
ers more frequently in migraine without aura (MO) [10],
while others report it more frequently in migraine with
aura (MA) [7]. Moreover, new WMHs may appear with
disease progression. The wide range of WMHs prevalence
is due to age and gender population differences, the
variety of slice thickness and magnetic ﬁeld strength MRI
scanners, and deﬁnition of WMHs (Table 1). The relationship
between the severity of migraine symptoms and the
presence of WMHs is not deﬁnitively established. While
Seneviratne et al. found correlation between WMHs and rate
of migraine attacks [11], Kruit et al. reported this relation-
ship only for females [6]. There are also papers where no
such correlation was established [7,12]. Although pathology
of WMHs is still not well known and may be multifactorial
[13], some authors claim that WMHs strongly correlate
with cerebrovascular diseases and risk factors related to
them [14,15] but other studies have not conﬁrmed that
ﬁnding [16–19].2. Material and methods
A total of 69 female patients with migraine, aged 18–60 yrs
(mean: 36.2  9.3) were included in the study: 38 women
with MO and 31 with MA. Minimal disease duration was of
one year with frequency of migraine attacks ranging from 1
to 8 per month. All the participants met the criteria of
migraine as deﬁned by ICHD-3 Beta Headache Classiﬁcation
Criteria 2013 [1], that was revised in 2018. All subjects were
diagnosed and evaluated in Neurology Outpatient Clinic.
The patients were consecutive women with the diagnosis of
migraine. We found only few male cases while recruiting
patients into the research. There are some evidence that the
incidence of WMH in brain may be dependent on gender and
because of relatively small group of our patients we decided
to not include males to avoid confusion and non-matched
gender population. The following inclusion criteria were
established: female sex, age ≤60 yrs, and absence ofsigniﬁcant risk factors for cardiovascular disease (hyperten-
sion, diabetes mellitus, coronary heart disease and throm-
boembolic disease). According to study protocol vital signs
and biometric parameters (weight, BMI) were assessed as
well as physical and neurological examinations were
performed. All participants completed the questionnaire
containing personal data, disease characteristics such as the
frequency and intensity of migraine pain in the past 3
months, pain location, type of migraine aura, the presence
of prodromal symptoms, the presence of menstrual mi-
graine pain, pregnancy history including spontaneous
abortions, family history of migraine, smoking, drinking
coffee, current treatment and MIDAS questionnaire asses-
sing migraine-related disability measured by reduced
number of days with normal functioning at work, household
chores and non-workers activity (social, family and leisure
activities) due to migraine in the last 3 months. The MIDAS
score was the sum of missed work days, household chores
days, non-work activity days, and days at work and days of
household chores where productivity was reduced. In
addition, serum homocysteine level in blood was measured.
Fasting serum was examined with CLIA analyzer ADVIA
Centaur XP by Siemens (reference range: 3.70–13.9 mmol/l).
Hyperhomocysteinaemia was determined at >15 mmol/l,
which is the most commonly used cut-off [26]. All patients
underwent brain magnetic resonance imaging (MRI) scans,
with OPTIMA MR 360 1.5T scanner. Imaging was performed
in FSE T1 sequence (axial plane, without and with contrast),
FR-FSE T2 sequence (axial, sagittal and coronal planes), IR-
FSE 2D T2 FLAIR sequence (axial, sagittal planes) and SE/EPI
DWI sequence (axial plane), 3 mm slices thickness. Initial
analysis was performed by a non-blinded radiologist who
evaluated the presence of pathology in the whole brain
without thorough analysis of the changes in the white
matter. Then, two independent researchers: a blinded
radiologist and a neurologist experienced in neuroimaging,
trained particularly in assessing of WMHs, assessed the
presence, number, anatomical location and size of WMHs. In
cases of doubts, decision to qualify the change as WMHs was
made jointly. To compare the results obtained in other
studies, the deﬁnition of WMHs foci was derived from the
consensus of the Standards for Reporting Vascular Changes
on Neuroimaging (STRIVE) 2013 [27], which is consistent
with the methods used in other studies [6,23]. According to
the STRIVE criteria, WMHs are hyperintensive in both T2
and FLAIR images, which could be seen as iso- or
hypointensive in T1-dependent images (Table 2). Number,
location and size of lesions were assessed in 2D FLAIR axial
plane, size of the foci was estimated using caliper similar to
the CAMERA study [6]. The changes were grouped according
to the location: lobes (frontal, parietal, temporal, occipital),
hemisphere (one and both hemispheres), artery circulation
territory (anterior cerebral artery, medial cerebral artery,
posterior cerebral artery), location in the white matter
(juxtacortical, subcortical, periventricular, infratentorial
using the Barkhof criteria for multiple sclerosis). Based on
the size of the foci, they were grouped into three subgroups:
small changes: ≤3 mm, medium: 4–6 mm and large: >6 mm –
similarly to other studies [23]. The study protocol was
approved by the Bioethics Committee.
Table 1 – Population-based studies and clinical-based studies of white matter hyperintensities in migraine.
Ref. MRI Slice
thickness
Population Number of
patients with
migraine
Age (yrs)
mean (SD)
MA:MO Women (%) WMHs
N
OR (95 CI) Number of
healthy controls
Population-based studies
CAMERA-1
Kruit et al.
2004 [6]
1.0–1.5T 3 mm Dutch 295 48.2 (0.6) MA
48.8 (0.7) MO
161:134 72 MA
75 MO
65 (22%)
34 (21%) MA
31 (23%) MO
MA 2.0
(1.0–4.3)
MO 2.1
(1.0-4.7)
140
EVA MRI
Kurth et al.
2011 [7]
1.0T 1.4 mm French 116 68.9 (2.8) 17:99 85.3 48 (41%)
10 (59%) MA
38 (38%) MO
MA 12.4
(1.6–99.4)
MO 1.6
(0.9–2.7)
617
CAMERA-2
Palm-Meinders
et al.
2012 [20]
Progression of
WMH in followed
up after 9 years
1.0–1.5T Not given Dutch 203 57 (7.3) 114:89 71 58 (29%)
33 (29%) MA
25 (28%) MO
Progression of WMHs
over time
2.1 (1.0–4.1)
83
ARIC MRI
Hamedani et al.
2013 [10]
Progression of
WMH in followed
up after 11 years
1.5T Not given American 1425 59 (5.4) MA
58 (5.5) MO
422:1003 82 MA
76 MO
Only severe WMHs
included
≥3 scores (range: 0–9)
(used CHS –
Cardiovascular Health
Study scale)
MA 0.55 (0.17–1.83)
MO 1.87 (1.04–3.37)
Progression of WMHs
over time MA 2.09
(0.99 to 5.16)
MO 1.86 (0.39 to 4.11)
10082
HUNT MRI
Honningsvåg
et al.
2015 [21]
1.5T Not given Norwegian 91 57.7 (4.3) Not given 73.6 9 (9.9%)
Only severe WMHs
included
≥2 Fazekas scores;
(range: 1–3)
Not given 552
Clinical-based studies
Rossato et al.
2009 [22]
1–1.5T 5 mm MA 185 36.0 (10) 185 MA 77 87 (47%) NA Not given
Trauninger et al.
2010 [17]
3.0T 3 mm MA + MO 186 35.4 (8.9) 45:141 83.9 58 (31.2%)
16 (35.6%) MA
42 (30.5%) MO
NA Not given
Seneviratne et al.
2012 [11]
1.5T 5 mm MA + MO 44 44.7 18:26 84 19 (43%)
12 (63.4%)MA
7 (36.8%)MO
NA Not given
Toghae et al.
2015 [12]
1.5T Not given MA + MO 90 36.1 (13.1) 20:70 76.7 29 (32.2%) NA Not given
Avci et al.
2015 [23]
1.5T 5 mm MA + MO 216 32.6 (3.9) MA
30.9 (7.6) MO
73:143 82.2 MA
73.4MO
69 (32%)
25 (34.2%) MA
44 (30.8%) MO
4.35 216
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n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 6 9 5 – 7 0 36982.1. Statistical analysis
Since the analyzed laboratory parameters were characterized
by quite signiﬁcant asymmetry of distribution, the tables
indicate the median value, which reﬂects better the average
level of these parameters. Statistical signiﬁcance of tested
dependencies was assessed with appropriate statistical tests:
the differences in the distribution of clinical parameters were
tested with the Mann–Whitney test, the comparison of
percentage distribution (or the incidence of certain health
events, including the presence, location of WMHs in MR) was
tested with chi-square independence test to evaluate the
signiﬁcance of differences between groups. Due to small
number of patients distributed in each group, Fisher's test was
used to assess statistical signiﬁcance of antimigraine drugs.
Probability value (p) was considered signiﬁcant at the level of
<0.05.
3. ResultsWMHswere found in 27 (39.1%) femaleswithmigraine,withno
correlation with migraine type: MA 10 (32.3%) vs. MO 17
(44.7%). The overall number of lesions was greater in MO (4.65
 3.97) than in MA (3.80  8.16); p = 0.027. It was found, that
older age, longer disease duration (Table 3) and BMI ≥ 25
(Table 4) were signiﬁcant risk factors for the incidence of
WMHs. There was no relationship between migraine severity
and WMHs prevalence (Table 3).
The type of aura, location ofmigraine pain had no inﬂuence
onWMHs. Prodromal symptomswere found less frequently in
WMH+ group (Table 4). Positive family history, regardless of
the proximity of kinship was not a risk factor for WMHs in
migraine females, whereas positive pregnancy history was
strongly correlated with the presence of WMHs (Table 4).
Precise analysis of WMHs+ who had been pregnant indicated
that the onset of migraine before pregnancy was the strongest
predilection factor for developing ofWMHs, irrespective of the
frequency ofmigraine attacks during the pregnancy time (data
not shown). All participants were analyzed with regard to the
presence of menstrual migraine pain, and this did not
correlate with the presence of WMHs (WMHs+ 19; 70.4% vs.
WMHs 23; 54.8%; p = 0.131).
Use of stimulants like smoking (WMHs+ n = 3; 11.1% vs.
WMHs n = 7; 16.7%; p = 0.561) or drinking coffee (WMHs+
n = 22; 81.5% vs. WMHs n = 29; 69.0%; p = 0.149) even with
respect to amount of cups of coffee (range: 1–4) consumed
during the day did not affect the presence of WMHs.
There was no correlation between the use of oral
contraceptive pills and the risk ofWMHs regardless of whether
the drugs were used in past or currently. Analysis of drugs
used to relieve the migraine pain: triptans, non-steroidal anti-
inﬂammatory drugs and used to prevent migraine attacks did
not correlate with the presence of WMHs but some of them
were used only in small number of patients (Table 5).
Radiological analysis of WMHs location in cerebral artery
circulation territory showed that WMHs in all females with
migraine were located in the anterior cerebral artery supplies,
less frequently in the middle cerebral artery supplies and only
in few cases in posterior cerebral artery supplies (Table 6). Also,
Table 2 – WMHs according to STRIVE consensus.
White matter hyperintensity
Localization White matter
DWI !
FLAIR "
T2 "
T1 !/#
T2*-weighted GRE "
Abbreviations: DWI, diffusion-weighted imaging; FLAIR, ﬂuid atte-
nuated inversion recovery; GRE, gradient-recalled echo. " increased
signal; # decreased signal; ! iso-intense signal.
n e u r o l o g i a i n e u r o ch i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 6 9 5 – 7 0 3 699the location in lobes does not depend on type of migraine.
Lesions were situated most frequently in frontal lobes, rarely
in parietal and temporal lobes, occasionally in occipital lobes.
In both groups, no infratentorial lesions were observed. The
type of migraine determined only location of WMHs regarding
one or both hemispheres. In MA dominated one-hemisphere
changes, in MO changes were present in both hemispheres.
Regardless of the nature of WMHs, white matter lesions were
located: mostly subcortically, rarely periventricularly and theTable 3 – Clinical characteristics of WMHs in patients with mig
WMHs+
(N = 27)
Mean (SD) Range (m
Age (yrs) 39.0 (8.3) 23.0
Age of onset (yrs) 16.0 (7.1) 8.0
Duration of migraine (yrs) 21.0 (11.7) 1.0
Intensity of migraine pain (range: 0–10) 8.0 (1.73) 4.0
Number of migraine attacks per month 3.0 (3.04) 1.0
Number of pain days per month 6.0 (3.78) 1.0
MIDAS scale 19.0 (23.0) 4.0
Serum homocysteine level (mmol/l) 14.8 (5.5) 6.1
Abbreviations: N, number of patients; SD, standard deviation; WMHs
hyperintensities absent.
Table 4 – Clinical characteristics of WMHs in migraine populat
WMHs +
(N = 27)
N % N
BMI <25 15 55.5% 33
BMI ≥25 12 44.4% 9
Pain location: bilateral 13 50.0% 15
Hemilateral/unilateral 12 44.4% 18
Hemilateral/alternating 10 37.0% 16
Type of migraine aura:
Visual 10 38.5% 20
Sensory 0 0.0% 3
Aphasic 0 0.0% 1
Prodromal symptoms 5 19.2% 21
Positive family history 17 65.4% 23
Positive pregnancy history 23 88.5% 25
Abbreviations: N, number of patients; WMHs+, present white matter hyp
group; BMI, Body Mass Index.
Probability value ( p) was considered signiﬁcant at the level of <0.05.least frequently juxtacortically. WMHswere assessed in terms
of their size: small lesions of ≤3 mmwere predominant in MO,
whereasmedium lesions (4–6 mm) and large (>6 mm) showed
similar prevalence in both groups (Table 7).
4. DiscussionWMHs are common ﬁndings in general population and can
correspond with normal aging process. In asymptomatic
healthy individuals WMHs correlate with age: in the forties
they are present in about 11% while in the seventies even in
83% [7]. These age related lesions are associated with
cardiovascular risk factors: hypertension, hypercholesterol-
emia, smoking and elevatedBMI [28–31]. Therefore, only young
andmiddle-agedwomen<60 years were included in our study
group,without any co-existing vascular disease risk factors. So
far, the presence of WMHs has been found to be independent
risk factors for ischemic stroke in general population [32,33]. In
the Rotterdam scan study, hyperintensive lesions among
elderly patients (>70 yrs) were predictive factors of ischemic
stroke [33]. According to other researchers, they were alsoraine.
WMHs
(N = 42)
p-Value
in–max) Mean (SD) Range (min–max)
–60.0 34.5 (9.4) 18.0–57.0 0.025
–38.0 19.5 (8.4) 11.0–43.0 0.126
–45.0 11.0 (7.7) 1.0–35.0 0.001
–10.0 8.0 (1.58) 1.0–12.0 0.411
–12.0 3.0 (2.55) 1.0–12.0 0.915
–15.0 5.0 (3.76) 1.0–15.0 0.188
–72.0 27.5 (20.1) 3.0–105.0 0.118
–35.8 14.2 (4.4) 7.2–24.7 0.306
+, white matter hyperintensities present; WMHs, white matter
ion.
WMHs
(N = 42)
p-Value Total
% N %
78.6% 0.042 48 69.5%
21.4% 0.042 21 30.4%
35.7% 0.244 28 41.2%
42.9% 0.896 30 43.5%
38.1% 0.929 26 37.7%
47.6% 0.459 30 44.1%
7.1% 0.163 3 4.4%
2.4% 0.428 1 1.5%
50.0% 0.011 26 38.2%
54.8% 0.387 40 58.8%
59.5% 0.010 48 70.6%
erintensities group; WMHs, absent white matter hyperintensities
Table 5 – Correlations of WMHs with medications.
Medication WMHs+
(N = 27)
WMHs
(N = 42)
p-Value Total
N % N % N %
Triptans 12 46.2% 18 42.9% 0.790 30 44.1%
Non-steroidal anti-inﬂammatory drugs 22 84.6% 35 83.3% 0.889 57 83.8%
Flunarizine 8 30.8% 11 26.2% 0.682 19 27.9%
Topiramate 3 11.5% 1 2.4% 0.118 4 5.9%
Iprazochrom 4 15.4% 10 23.8% 0.403 14 20.6%
Oral contraceptive pills (ever) 6 23.1% 9 21.4% 0.873 15 22.1%
Abbreviations: N, number of patients tested; WMHs+, white matter hyperintensities present; WMHs, white matter hyperintensities absent.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 6 9 5 – 7 0 3700predictor of recurrent ischemic stroke or stroke after transient
ischemic attack (TIA) [34]. Migraine, especially MA correlates
with increased risk of cerebrovascular disease [7,35] and this
higher risk is present among women, particularly those
smoking and using oral contraceptive pills [7,36,37] with
pronounced predilection to subclinical infarcts in the posterior
circulation territory, especially in the cerebellum [6,32,37–40].
Population Reykjavik Study proved that only middle-aged
women with MA are predisposed to appear silent infarct-like
lesions in late-life and that these lesions involve only the
cerebellum [39]. Similar correlations were found in the studies
regarding WMHs. In the CAMERA-1 population study in-
creased risk for deep WMHs in both MA and MO was found
only for women irrespective of other risk factors occurrence
[6]. Analysis of supratentorially located WMHs progression
over time showed that increasing number of these changes
were found only in females [20].
Numerous studies have shown that the risk of WMHs in
migraine is signiﬁcantly increased (Table 1). The prevalence of
WMHs seems to be higher in studies, in which participants
have multiple vascular disease risk factors and are usually
older (compare CAMERA-1 and EVA-MRI studies, Table 1). The
lowest prevalence was found in the HUNT MRI population
study, which only assessed the presence of severe hyper-
intensive lesions (Fazekas score ≥2 points, range 1–3) [21].
There is heterogeneity when it comes to MRI protocols. TheTable 6 – Radiological localization of brain WMHs in migraine
WMHs location Total
N % MO
N
ACA supplies 27 100.0% 17
MCA supplies 7 25.9% 5
PCA supplies 2 7.4% 1
One hemisphere 14 51.9% 6
Both hemispheres 13 48.1% 11
Subcortical 25 92.6% 16
Periventricular 4 14.8% 2
Juxtacortical 3 11.1% 3
Frontal lobe 25 92.6% 16
Parietal lobe 6 22.2% 4
Temporal lobe 3 11.1% 2
Occipital lobe 2 7.4% 1
Abbreviations: N, number of patients tested; ACA, anterior cerebral artery
white matter hyperintensities; MO, migraine without aura; MA, migrainemost popular one are 1.5 Tesla scanners [11,12,22–24], while
only in two studies 3 Tesla scanners were used [17,25]. The
WMHs prevalence in studies that used 3T ﬁeld scanners (31.2–
32%) was not higher than 1.5 Tesla scanners studies (22–40%).
WMHs prevalence seems to be not associated with slice
thickness in MRI. Studies that used 1.4 mm, 3 mm and 5 mm
showed WMHs in 41%, 22–32%, and 32–43% of patients,
respectively (Table 1). The prevalence of WMHs in our study
(39.1%) was similar to previous ﬁndings [11,24]. In both these
studies MRI methodology as well as group selection with
regard to age, sex and proportion of patients with MA and MO
were comparable with our study (Table 1). According to some
researchers, the risk of WMHs is signiﬁcantly higher in MA
[6,41]. In our study, as in some previous reports, there was a
similar risk of WMHs in both MA and MO subtypes [17,42] and
the presence of aura, aura type and pain location were not
conﬁrmed as predictive factors for WMHs, as was previously
noted [12]. We found that age and overweight (BMI ≥ 25) were
independent risk factors for WMHs prevalence in migraine
patients which was consistent with other results [11,12,22,23].
So far the origin of WMHs is still unclear. Many possible
pathophysiological theories of WMHs have been proposed:
repeated, prolonged oligemia, blood-brain barrier dysfunction,
mitochondrial dysfunction, oxidative stress, endothelial dys-
function, patent foramen ovale with right to left shunt,
vascular wall inﬂammation [42,43]. It is believed that WMHspatients.
Type of migraine p-Value
(N = 17) MA (N = 10)
% N %
100.0% 10 100.0% 1.000
29.4% 2 20.0% 0.590
5.9% 1 10.0% 0.693
35.3% 8 80.0% 0.024
64.7% 2 20.0% 0.024
94.1% 9 90.0% 0.693
11.8% 2 20.0% 0.560
17.6% 0 0.0% 0.158
94.1% 9 90.0% 0.693
23.5% 2 20.0% 0.831
11.8% 1 10.0% 0.880
5.9% 1 10.0% 0.693
; MCA, medial cerebral artery; PCA, posterior cerebral artery; WMHs,
with aura.
Table 7 – WMHs size in migraine patients.
WMHs size Type of migraine p-Value Total
MO (N = 17) MA (N = 10) N %
N % N %
Small (≤3 mm) 16 94.1% 6 60.0% 0.027 22 81.5%
Medium (4–6 mm) 11 64.7% 6 60.0% 0.806 17 63.0%
Large (>6 mm) 0 0.0% 1 10.0% 0.184 1 3.7%
Abbreviations: MO, migraine without aura; MA, migraine with aura.
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oligodendroglial cells [44]. The cause is commonly interpreted
as ischemic. One of the hypotheses suggests that these
neuropathological changesmay be the result of hemodynamic
ischemia induced by lipohyalinosis of perforating arteries and
small vessels. These abnormalities may underlie the patholo-
gy ofWMHs located in deepwhitematter of the brain. Damage
of ventricular system's endothelium followed by widening of
the subendothelial extracellular space results in blood brain
barrier injury and periventricular white matter changes [28]. It
is known, that during a migraine attack, regional cerebral
blood ﬂow is decreased, mainly in the parietal-occipital area
spreading to frontal area or exclusively in frontal lobes [45] and
does not affect neurovascular boundaries [46]. Nevertheless it
may cause local reversible ischemia that, in case of a reduction
above the threshold of ischemia, can lead to ischemic stroke
[47]. We found, that almost all WMHs were located in frontal
lobes, so this could conﬁrm rather the second hypothesis. It is
also believed, that recurrent migraine attacks and prolonged
oligaemia may cause damage of small perforating arteries
resulting in local hypoperfusion and, as a result, occurrence of
WMHs, that are often interpreted as an independent markers
of local brain hypoperfusion [25].
We assumed, that repeated vascular dysfunction causes
local ischemia andmay be the cause ofWMHs. That is why we
investigated the correlation between WMHs, the frequency of
migraine attacks and duration of the disease. However, we
found that migraine severity measured by the frequency of
attacks per month, pain intensity or impairment in MIDAS
scale did not inﬂuence on WMHs prevalence. These results of
our study are in line with other ﬁndings [6,7,20,25]. However,
others reported that increasing headache frequency was
associated with higher WMHs prevalence in MO [11,17,18].
The reason of lack ofWMHs correlationwithmigraine severity
in our study may be due to assessment of migraine's
parameters only in the last 3 months, not covering the
duration of disease. And it is known that migraine is
characterized by variability, both exacerbations and remission
depend not only on successful therapy but also on numerous
other factors. However, we have conﬁrmed, as in other studies
[12,17] that longer duration of the disease, irrespective of age of
the patients, is a risk factor for the occurrence of WMHs
indicating that these changes are developing over time.
Surprisingly, we found prodromal symptoms to be protective
against WMHs occurring which had not been reported before.
We can speculate that pathomechanisms involved in devel-
oping of prodromal symptoms and WMHs are different.
Hyperhomocysteinemia is known to be signiﬁcant risk
factor for ischemic stroke caused by small arteries occlusion(lacunar strokes) [48]. According to some authors it is
independent predictor of WMHs in the healthy elderly
regardless of smoking, hypertension or age [49]. Some
researchers found increased homocysteine serum level in
migraine patients [50]. However, as in previous studies [19,20],
no association ofWMHs occurrencewith serumhomocysteine
level in migraine was found in our study.
The fact that, according to some authors, increased risk of
WMHs in migraine patients is limited only to women [10,20],
imposed the questions about the effect of oral contraceptive
pills and pregnancy. It is known that ﬂuctuations in hormone
levels occurring in the menstrual cycle affect the risk of
migraine. Menstruation is an important risk factor for MA [51]
and pregnancy, especially in women with menstrual
migraines, improves the course of MO, whereas MA may
manifest for the ﬁrst time in the ﬁrst and second trimesters
[52]. In our studywe found link betweenpregnancyhistory and
WMHs regardless of migraine clinical course during pregnan-
cy. This ﬁnding may suggest that changes in the haemostatic
system typical for pregnancy with pro-coagulant stimulation
and decrease in ﬁbrinolysis may induce an activation of the
WMHs pathophysiological process.
We have not found any correlation betweenWMHs and the
use of oral contraceptives which is in line with other studies
[6,12,16,53]. Only the CAMERA study showed relationship
betweenWMHs and long-term use of oral contraceptives (>15
years). Smoking is an important atherogenic factor leading to
numerous cardiovascular diseases that is why correlation
between WMHs and smoking was analyzed. As in previous
reports [12], we found no correlationwith smoking. The reason
of this may be smoking is rather related to atherosclerosis of
large vessels and WMHs, if of vascular etiology, result from
small vessels pathology.
Our study provides descriptions of the WMHs distribution
in the brain. The results conﬁrmed previous outcomes that
showed the presence of WMHs in supratentorial region, in
anterior cerebral artery circulation territory, mainly in the
frontal lobes, and mostly located subcortically
[6,11,12,22,23,54]. Based on MRI ﬁndings, we were able to
classify WMHs in migraine females as subcortical and deep
white matter lesions because periventricular white matter
changes and juxtacortical lesions were found rare. As in one
previous report [11], in our study there were no infratentorial
abnormalities. Nevertheless, other studies described this
location in individual cases [6,23]. A clear predilection for
frontal lobe location is consistent with other studies [11,22,54].
In the majority of females with migraine (81.5%), as in other
studies [23], determined lesions were small (≤3 mm). In our
study it was also found that WMHs in patients with MA were
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 6 9 5 – 7 0 3702predominantly located in one hemisphere, and even though
themajority ofMApatient had visual aura, the occipitalWMHs
location was rare. On the other hand WMHs in MO females
were found mainly in both hemispheres, being signiﬁcantly
higher in number than inMA. These ﬁndingsmay conﬁrm that
aura is not a risk factor for WMHs inmigraine females and the
presence and distribution of WMHs are related to migraine
itself rather than aura.
Our study provides additional data on the white matter
hyperintensity risk factors in migraine females, particularly
positive history of pregnancy, that could be useful to better
understanding of the WMHs pathophysiology in future
population studies.
5. Conclusions1. WMHs are present in more than one third of migraine
females regardless of presence of aura.2. WHMs are exclusively located supratentorially, subcorti-
cally, and mainly in frontal lobes.3. Older age, longer duration of disease, obesity and positive
history of pregnancy are main risk factors for WMHs and
might provide arguments for vascular etiology of these
changes.4. Symptomatology and migraine severity, hyperhomocystei-
nemia, use of oral contraceptive pills and anti-migraine
medications do not correlate with the developing ofWMHs.Conﬂicts of interestNone declared.
Acknowledgement and ﬁnancial supportNone declared.r e f e r e n c e s
[1] Headache Classiﬁcation Committee of the International
Headache Society (HIS). The International Classiﬁcation of
Headache Disorders, 3rd edition (beta version). Cephalalgia
2013;33:629–808.
[2] Committee of the Global Burden of Disease Study 2015.
Global, regional, and national incidence, prevalence, and
years lived with disability for 310 diseases and injuries,
1990–2015: a systematic analysis for the Global Burden of
Disease Study 2015. Lancet 2016;388:1545–602.
[3] Lyngberg AC, Rasmussen BK, Jørgensen T, Jensen R. Secular
changes in health care utilization and work absence for
migraine and tension-type headache: a population based
study. Eur J Epidemiol 2005;20:1007–14.
[4] Stępień A, Prusiński A, Suwała A. Wybrane dane
epidemiologiczne migreny w Polsce. Ból 2003;4(3):9–12.
[5] Bigal ME, Liberman JN, Lipton RB. Age-dependent
prevalence and clinical features to migraine. Neurology
2006;67:246–51.[6] Kruit MC, van Buchem MA, Hofman PA, Bakkers JT,
Terwindt GM, Ferrari MD, et al. Migraine as a risk factor for
subclinical brain lesions. JAMA 2004;291:427–34.
[7] Kurth T, Mahomed S, Maillard P, Yi-Cheng Z, Chabriat H,
Mazoyer B, et al. Headache, migraine and structural brain
lesions and function: population based epidemiology of
vascular ageing-MRI study. BMJ 2011;342. http://dx.doi.org/
10.1136/bmj.c7357
[8] Bashir A, Lipton RB, Ashina S, Ashina M. Migraine and
structural changes in the brain: a systematic review and
meta analysis. Neurology 2013;81:1260–8.
[9] Monteith T, Gardener H, Rundek T, Dong Ch, Yoshita M,
Elkind MSV, et al. Migraine, white matter hyperintensities
and subclinical brain infarction in a diverse community: the
NOMAS Study. Stroke 2014;45(6):1830–2.
[10] Hamedani AG, Rose KM, Peterlin BL, Mosley TH, Coker LH,
Jack CR, et al. Migraine and white matter hyperintensities:
the ARIC MRI study. Neurology 2013;81(15):1308–13.
[11] Seneviratne U, Chong W, Billimoria PH. Brain matter
hyperintensities in migraine: clinical and radiological
correlates. Clin Neurol Neurosurg 2013;115:1040–3.
[12] Toghae M, Rahimian E, Abdollahi M, Shoar S, Naderan M.
The prevalence of magnetic resonance imaging
hyperintensity in migraine patients and its association
with migraine headache characteristics and cardiovascular
risk factors. Oman Med J 2015;30(3):203–7.
[13] Gouw AA, Seewann A, van der Flier WM, Barkhof F,
Rozemuller AM, Scheltens P, et al. Heterogeneity of small
vessel disease: a systematic review of MRI and
histopathology correlations. J Neurol Neurosurg Psychiatry
2011;82:126–35.
[14] Debette S, Markus HS. The clinical importance of white
matter hyperintensities on brain magnetic resonance
imaging: systematic review and meta-analysis. BMJ
2010;341. http://dx.doi.org/10.1136/bmj.c3666
[15] Scher AI, Terwindt GM, Picavet HS, Verschuren WM, Ferrari
MD, Launer LJ. Cardiovascular risk factors andmigraine: the
GEM population-based study. Neurology 2005;64(4):614–20.
[16] Swartz RH, Kern RZ. Migraine is associated with magnetic
resonance imaging white matter abnormalities: a meta
analysis. Arch Neurol 2004;61(9):1366–8.
[17] Trauninger A, Leél-Ossy E, Kamson DO, Poto L, Aradi M,
Kover F, et al. Risk factors of migraine-related brain white
matter hyperintensities: an investigation of 186 patients. J
Headache Pain 2011;12(1):97–103.
[18] López-Mesonero L, Márquez S, Parra P, Gamez-Leyva L,
Munoz P, Pasqual J. Smoking as a precipitating factor for
migraine: a survey in medical students. J Headache Pain
2009;10(2):101–3.
[19] Rao R, Tah V, Casas JP, Hingorani A, Whittaker J, Smeeth L,
et al. Ischaemic stroke subtypes and their genetic basis: a
comprehensive meta-analysis of small and large vessel
stroke. Eur Neurol 2009;61(2):76–86.
[20] Palm-Meinders IH, Koppen H, Terwindt GM, Launer LJ,
Konishi J, Moonen JME, et al. Structural brain changes in
migraine. JAMA 2012;308(18):1889–97.
[21] Honningsvåg LM, Hagen K, Håberg A, Stovner LJ, Linde M.
Intracranial abnormalities and headache: a population-
based imaging study (HUNT MRI). Cephalalgia 2016;36
(2):1130–2121.
[22] Rossato G, Adami A, Thijs VN, Cerini R, Pozzi-Mucelli R,
Mazzucco S, et al. Cerebral distribution of white matter
lesions in migraine with aura patients. Cephalalgia 2010;30
(7):855–9.
[23] Avci AY, Lakadamyali H, Arikan S, Benli US, Kilinic M. High
sensitivity C-reactive protein and cerebral white matter
hyperintensities on magnetic resonance imaging in
migraine patients. J Headache Pain 2015;16:16–9. http://dx.
doi.org/10.1186/1129-2377-16-9
n e u r o l o g i a i n e u r o ch i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 6 9 5 – 7 0 3 703[24] Vijiaratnam N, Barber D, Lim KZ, Paul E, Jiang M, Chosich B,
et al. Migraine: does aura require investigation? Clin Neurol
Neurosurg 2016;148:110–4.
[25] Zhang Q, Datta R, Detre JA, Cucchiara B. White matter
lesion burden in migraine with aura may be associated
with reduced cerebral blood ﬂow. Cephalalgia 2017;37
(6):517–24.
[26] Refsum H, Smith AD, Ueland PM. Facts and
recommendations about total homocysteine
determinations: an expert opinion. Clin Chem 2004;50:3–32.
[27] International Working Group from Centres of Excellence in
Neurodegeneration. Neuroimaging standards for research
into small vessel disease and its contribution to ageing and
neurodegeneration. Lancet Neurol 2013;12:822–38.
[28] Xiong YY, Mok V. Age-related white matter changes. J Aging
Res 2011;27. http://dx.doi.org/10.4061/2011/617927
[29] Knopman DS, Penman AD, Catellier DJ, Coker LH, Shibata
DK, Sharrett AR, et al. Vascular risk factors and longitudinal
changes on brain MRI: ARIC study. Neurology 2011;76
(22):1879–85.
[30] Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T,
et al. Migraine and cardiovascular disease: systematic
review and meta-analysis. BMJ 2009. http://dx.doi.org/
10.1136/bmj.b3914
[31] Gudmundsson LS, Scher AI, Aspelund T, Eliasson JH,
Johannsson M, Thorgeirsson M, et al. Migraine with aura
and risk of cardiovascular and all cause mortality in men
and women: prospective cohort study. BMJ 2010;341. http://
dx.doi.org/10.1136/bmj.c3966
[32] Buyck JF, Dufouil C, Mazoyer B, Maillard P, Ducimetiere P,
Alperovitch A, et al. Cerebral white matter lesions are
associated with the risk of stroke but not with other
vascular events: the 3-City Dijon Study. Stroke 2009;40
(7):2327–31.
[33] Vermeer SE, Hollander M, van Dijk EJ, Hofman A, Koudstaal
PJ, Breteler MM, et al. Silent brain infarcts and white matter
lesions increase stroke risk in the general population: the
Rotterdam Scan Study. Stroke 2003;34(5):1126–9.
[34] Kuller L, Longstreth W, Arnold A. White matter
hyperintensity on cranial magnetic resonance imaging: a
predictor of stroke. Stroke 2004;35:1821–5.
[35] Kurth T, Gaziano JM, Cook NR, Bubes V, Logroscino G,
Diener HC, et al. Migraine and risk of cardiovascular disease
in women. JAMA 2006;296(3):283–91.
[36] Etminan M, Takkouche B, Isorna FC, Samii A, et al. Risk of
ischemic stroke in people with migraine: systemic review
and meta-analysis of observational studies. BMJ
2005;330:63. http://dx.doi.org/10.1136/bmj.38302.504063.8F
[37] MacClellan LR, Giles W, Cole J, Wozniak M, Stern B, Mitchel
BD, et al. Probable migraine with visual aura and risk of
ischemic stroke: the stroke prevention in young women
study. Stroke 2007;38(9):2438–45.
[38] Milhaud D, Bogousslavsky J, van Melle G, Liot P. Ischemic
stroke and active migraine. Neurology 2001;57(10):1805–11.
[39] Scher AI, Gudmundsson LS, Sigurdsson S, Ghambaryan A,
Aspelund T, Eiriksdottir G, et al. Migraine headache inmiddle-age and late-life brain infarcts: the age gene/
environment susceptibility – Rekjavik study. JAMA 2009;301
(24):2563–70.
[40] Kuller LH, Longstreth Jr WT, Arnold AM, Bernick C, Bryan
RN, Beauchamp NJ, et al. White matter hyperintensity on
cranial magnetic resonance imaging: a predictor of stroke.
Stroke 2004;35(8):1821–5.
[41] Kruit MC, Launer LJ, Ferrari MD, van BuchemMA. Infarcts in
the posterior circulation territory in migraine: the
population-based MRI CAMERA study. Brain 2005;128:2068–
77.
[42] Degirmenci B, Yaman M, Haktanir A, Albayrak R, Acar M,
Yucel A, et al. Cerebral and cerebellar ADC values during a
migraine attack. Neuroradiology 2007;49(5):419–26.
[43] Colombo B, Dalla Libera D, Comi G. Brain white matter
lesions in migraine: what's the meaning? Neurol Sci 2011;32
(Suppl.):37–40.
[44] Vuorinen M, Solomon A, Rovio S, Nieminen L, Kareholt I,
Tuomilehto J, et al. Changes in vascular risk to late life and
white matter lesions: a 20-year follow up study. Dement
Geriatr Cogn Disord 2011;31(2):119–25.
[45] Afridi SK, Gifﬁn NJ, Kaube H, Friston KJ, Ward NS,
Frackowiak RSJ, et al. A position emission tomographic
study in spontaneous migraine. Arch Neurol 2005;62:1270–
5.
[46] Eikermann-Haerter K, Moskowitz MA. Animal models of
migraine headache and aura. Curr Opin Neurol 2008;21
(3):294–300.
[47] Wolf ME, Szabo K, Griebe M, Forster A, Gass A, Hennerici
MG, et al. Clinical and MRI characteristics of acute
migrainous infarction. Neurology 2011;76(22):1911–7.
[48] Perini F, Galloni E, Bolgan I, Bader G, Rufﬁni R, Arzenton E,
et al. Elevated plasma homocysteine in acute stroke was
not associated with severity and outcome: stronger
association with small artery disease. Neurol Sci 2005;26
(5):310–8.
[49] Dufouil C, Alpérovitch A, Ducros VD, Tzourio Ch.
Homocysteine, white matter hyperintensities and
cognition in healthy elderly people. Ann Neurol 2003;53
(2):214–21.
[50] Gavgani SC, Hoseinian MM. Comparative study on
homocysteine levels in migraine patients and normal
peoples. Ann Biol Res 2012;3:1804–7.
[51] MacGregor EA, Hackshaw A. Prevalence of migraine on each
day of the natural menstrual cycle. Neurology 2004;63
(2):351–3.
[52] MacGregor EA. Headache in pregnancy. Continuum
2014;20:128–47.
[53] Rao R, Rosati A, Liberini P, Gipponi S, Venturelli E, Sapia E,
et al. Cerebrovascular risk factors and MRI abnormalities in
migraine. Neurol Sci 2008;29(Suppl. 1):144–5.
[54] Erdélyi-Bótor S, Aradi M, Kamson DO, Kovacs N, Perlaki G,
Orsi G, et al. Changes of migraine-related white matter
hyperintensities after 3 years: a longitudinal MRI study.
Headache 2015;55(1):55–70.
